Objective To discuss the influence and curative effect of Montelukast on serum IL -6 and IL-10 levles of children withrespiratory syncytial virus (RSV) bronchiolitis.Methods Eighty cases of children with RSV bronchiolitis were selected and randomlydivided into experimental group and control group .The children in two groups were given anti-virus, inhalation of Budesonide and othersupporting symptomatic treatment until the transference cure .The children in the experimental group were additionally given 2.5mgMontelukast dulcets orally at bed-time for 3 months.The changes of serum IL-6 and IL-10 levels of children in two groups were observedbefore and after 3 months’ medical treatment, and the gasping reoccurrence rate was followed up and observed at the time of half -a-yearand one year after medical treatment.Results There were no significant differences in the serum levels of IL -6 and IL-10 before treatment(t =0.19,P >0.05).The serum level of IL-6 decreased significantly after 3 months of treatment in two groups (t value was 2.95 and2.26, respectively, both P <0.05), but the serum level of IL-10 increased significantly (t value was 2.91 and 2.35, respectively, both P <0.05).The serum level of IL-6 in the experimental group was significantly lower than that in the control group (t =2.31,P <0.05), but the serum level of IL-10 in the experimental group was significantly higher than that in the control group (t =2.21,P <0.05).Thereoccurrence rate was significantly lower in the experimental group than in the control group after followed -up for a half year and one yearafter medical treatment (χ2 value was 4.50 and 5.23, respectively, both P <0.05).Conclusion Montelukast has reliable curative effect onRSV bronchiolitis, and can obviously reduce the gasping reoccurrence rate .The mechanism of action has close relationship with reducingthe serum level of IL-6, enhancing the serum level of IL-10 and adjusting the imbalance of serum inflammatory factor level .%目的：探讨孟鲁司特对呼吸道合胞病毒（RSV）毛细支气管炎患儿血清白介素–6（IL-6）和白介素–10（IL-10）水平的影响及疗效观察。方法选择80例RSV毛细支气管炎患儿，随机分为实验组和对照组。两组患儿均予以抗病毒、布地奈得雾化吸入及对症支持治疗，症状消失后停药。实验组在此基础上予以孟鲁司特咀嚼片2．5mg，睡前口服，连用3个月。对照组除不使用孟鲁司特咀嚼片外，余治疗同实验组。观察两组患儿治疗前和治疗3个月后的血清IL-6和IL-10水平的变化，并随访观察治疗后半年和1年内喘息复发率。结果两组患儿治疗前血清IL-6和IL-10水平比较差异无统计学意义（t＝0．19，P＞0．05）。治疗3个月后，两组患儿血清IL-6水平均显著下降（t值分别为2．95、2．26，均P＜0．05），IL-10水平均显著上升（t值分别为2．91、2．35，均P＜0．05），且实验组患儿IL-6水平显著低于对照组（t＝2．31，P ＜0．05），IL-10水平显著高于对照组（t＝2．21，P＜0．05）。实验组治疗后随访观察半年和1年内其喘息复发率均明显低于对照组（χ2值分别为4．50、5．23，均P＜0．05）。结论孟鲁司特治疗RSV毛细支气管炎的疗效确切，能明显能减少喘息的复发率，作用机制与其降低血清IL-6水平，升高血清IL-10水平，调节血清炎症因子水平失衡密切相关。
展开▼
